Navigation Links
Activation of microRNA inhibits cancer gene in human cancer cells

Scientists report that tumor cells display a dramatic reduction of cancer-causing genes when a newly discovered method is used to activate the expression of protective microRNAs in the cancer cell genome. The research, published in the June issue of Cancer Cell, demonstrates that agents known to regulate gene expression can also impact regulatory RNAs that may function as tumor suppressors in normal cells and proposes a novel strategy for treating human cancers.

DNA methylation and histone deacetylation are epigenetic processes involved in the regulation of gene expression. In the case of cancer, these processes are thought to turn off genes that may protect cells from abnormal cell growth. Drugs that inhibit DNA methylation and histone deacetylation, known as chromatin-modifying drugs, can reactivate genes that have been abnormally silenced in cancer cells. It is conceivable that these processes may also regulate expression of some RNAs.

MicroRNA (miRNA) is small and noncoding RNA that can regulate gene expression by inhibiting protein translation. Recent research has implicated miRNAs in cancer development and has led to the observation that some miRNAs are reduced in various human cancers and may normally function as tumor suppressors. According to study author Dr. Peter A. Jones from the Norris Comprehensive Cancer Center at the University of Southern California in Los Angeles, "Although the biological importance of miRNA is becoming increasingly apparent, regulation of miRNA expression is not fully understood."

Dr. Jones and his colleagues examined whether miRNAs can be controlled by epigenetic alterations linked to chromatin remodeling. Cancer cells and normal cells were treated with chromatin-remodeling drugs to simultaneously inhibit DNA methylation and histone deacetylation. A subset of miRNAs was upregulated in the cancer cells but not the normal cells. Importantly, miR-127, which is downregulated in 75% of the human cancer cells t ested, was highly induced after treatment with the chromatin-remodeling drugs. Induction of miR-127 resulted in downregulation of BCL6, a known proto-oncogene. Therefore, induction of miR-127 by treatment with chromatin-remodeling drugs may have an anticancer effect.

"Taken together, our results suggest an effect of epigenetic treatment that couples inhibitors of DNA methylation and histone deacetylation to induction of some miRNAs. These miRNAs can potentially regulate expression of target genes that are important in the development and progression of human cancer. Further studies on epigenetic regulation of miRNA expression are necessary, and regulation of miRNA expression by epigenetic treatment may be a novel strategy for prevention or treatment of human cancer," offers Dr. Jones.


'"/>

Source:Cell Press


Related biology news :

1. An HIV Protein Plays a Surprising Role in Gene Activation
2. Activation of thermoreceptors mediates raw garlics burning pungency
3. Activation of a protein solidifies fear memory in the brain
4. NYU, Rockefeller researchers find complexity of regulation by microRNA genes
5. Molecular steps involved in the creation of gene-silencing microRNAs identified
6. Scientists find microRNAs regulate plant development
7. Role of microRNA identified in thyroid cancer
8. Twin molecular scissors link creation of microRNAs with gene-silencing
9. Single microRNA causes cancer in transgenic mouse
10. Pair of microRNA molecules controls major oncogene in most common leukemia
11. Unicellular microRNA discovery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... development of innovative products and services, announced today that ... denied its petition to review decisions by ... Patent No. 6,258,540 (",540 Patent") are not patent eligible ... Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  In ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
Breaking Biology Technology: